Bristol-Myers Squibb AI Stock Analysis
Want to see BMY full AI Analyst Report?
Bristol-Myers Squibb (BMY) AI Stock Analysis
Bristol-Myers Squibb
(NYSE:BMY)
The score is driven primarily by solid financial performance (strong current margins and cash generation, tempered by leverage and earnings/FCF volatility) and a constructive earnings update (raised guidance and strong growth-portfolio/pipeline momentum despite Eliquis LOE risk). Valuation is supportive due to a moderate P/E and high dividend yield, while technical indicators are neutral-to-mixed and do not add strong momentum support.
Bristol-Myers Squibb Key Performance Indicators (KPIs)
Revenue by SegmentAnalyzes revenue from different business segments, highlighting which areas drive growth and profitability, and indicating how well the company diversifies its income streams.
Product revenue has shifted from steady to accelerating in H1‑2026, reflecting the Eliquis-led and broader growth‑portfolio strength that underpins management’s raised guidance; this makes product performance the primary driver of near‑term upside. “Other” has become a noticeably lumpier but slightly larger contributor since late‑2024, adding volatility rather than scale, while Alliance receipts are flat-to-declining, signaling limited partner upside. The stock’s path now hinges on sustaining Eliquis/growth product momentum and successful launches—legacy generic pressure and Opdivo softness remain the main downside risks.
Bristol-Myers Squibb (BMY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $128.63B
- Dividend Yield
- 4.00%
- Average Volume (3M)
- 10.96M
- Price to Earnings (P/E)
- 13.9
- Beta (1Y)
- 0.24
- Revenue Growth
- 4.19%
- EPS Growth
- 52.55%
- Country
- US
- Employees
- 32,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Bristol-Myers Squibb Business Overview & Revenue Model
Company Description
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hemato...
How the Company Makes Money
BMS makes money primarily by selling branded prescription drugs. Revenue is recognized from product sales to wholesalers, specialty distributors, hospitals, and other customers, with net sales reflecting typical industry deductions such as government...
Bristol-Myers Squibb Earnings Call Summary
The call was strongly positive overall. Management reported 7% total revenue growth, 12% growth in the growth portfolio, strong performance from multiple key brands, raised full-year guidance, substantial cash generation, and several positive late-stage pipeline readouts. The principal challenges were the upcoming Eliquis loss of exclusivity, declines in parts of the legacy portfolio and Opdivo, execution issues for Cobenfy, uncertainty around the higher admilparant dose, and the Zolacel program pause following a fatal event. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Bristol Myers Squibb increased its full year revenue guidance; its expected non GAAP EPS guidance range for 2026 is now $6.35 to $6.55, and excluding the third quarter acquired in process R&D charges and licensing income of $0.58 per share, the midpoint would have increased by approximately $0.15 per share. The company is maintaining its projections for gross margin, operating expenses, and tax rate, while slightly lowering the expense level on its other income and expense line; total legacy portfolio revenue decrease is now expected to be between 3% to 5%, while Eliquis full year revenue growth is expected to be 20% to 25%. For 2027, Eliquis is expected to have a $1.5 billion to $2 billion step down, and the strategic productivity initiative is on track to achieve $2 billion worth of efficiencies by the end of 27; the company also expects physicians to convert at least 30% to 40% of IV business to Qvantig, tracking towards the higher end of that range.
Bristol-Myers Squibb Financial Statement Overview
Summary
Solid current profitability and cash generation (TTM net margin ~18%, EBIT margin ~20%, strong historical FCF-to-net-income conversion), but the profile is held back by a leveraged balance sheet in the annual data and notable earnings volatility (2024 loss followed by a sharp rebound). Recent free cash flow growth turning negative also reduces confidence in near-term cash momentum.
Income Statement
74PositiveBalance Sheet
52NeutralCash Flow
71Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.03B | 48.20B | 48.30B | 45.01B | 46.16B | 46.38B |
| Gross Profit | 34.64B | 34.26B | 34.33B | 34.31B | 36.02B | 36.45B |
| EBITDA | 15.15B | 15.23B | 3.17B | 19.37B | 19.22B | 20.12B |
| Net Income | 9.24B | 7.05B | -8.95B | 8.03B | 6.33B | 6.99B |
Balance Sheet | ||||||
| Total Assets | 88.77B | 90.04B | 92.60B | 95.16B | 96.82B | 109.31B |
| Cash, Cash Equivalents and Short-Term Investments | 12.58B | 10.67B | 10.86B | 12.28B | 9.25B | 17.22B |
| Total Debt | 44.81B | 47.14B | 51.20B | 41.46B | 40.72B | 45.60B |
| Total Liabilities | 65.37B | 71.53B | 76.22B | 65.67B | 65.70B | 73.31B |
| Stockholders Equity | 23.40B | 18.47B | 16.34B | 29.43B | 31.06B | 35.95B |
Cash Flow | ||||||
| Free Cash Flow | 9.29B | 12.85B | 13.94B | 12.65B | 11.95B | 15.23B |
| Operating Cash Flow | 10.65B | 14.16B | 15.19B | 13.86B | 13.07B | 16.21B |
| Investing Cash Flow | -5.31B | -4.13B | -21.35B | -2.29B | -1.06B | -538.00M |
| Financing Cash Flow | -11.44B | -10.35B | 5.13B | -9.42B | -16.96B | -16.22B |
Bristol-Myers Squibb Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMY, the sentiment is Positive. The current price of 62.93 is above the 20-day moving average (MA) of 62.28, above the 50-day MA of 61.59, and above the 200-day MA of 59.40, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 53.79 is Neutral, neither overbought nor oversold. The STOCH value of 37.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BMY.
Bristol-Myers Squibb Risk Analysis
Bristol-Myers Squibb disclosed 23 risk factors in its most recent earnings report. Bristol-Myers Squibb reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskBristol-Myers Squibb Peers Comparison
Overall Rating
LLY81Outperform
AMGN75Outperform
NVS72Outperform
ABBV71Outperform
BMY69Neutral
MRK64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $1.35T | 46.54 | 83.65% | 0.48% | 45.51% | 50.48% | |
| 75Outperform | $250.07B | 26.65 | 85.59% | 2.15% | 8.60% | 33.48% | |
| 72Outperform | $295.59B | 31.08 | 24.24% | 2.96% | 1.64% | -28.72% | |
| 71Outperform | $520.65B | 50.56 | -202.43% | 2.35% | 10.68% | 338.08% | |
| 69Neutral | $128.63B | 13.94 | 43.88% | 4.00% | 4.19% | 52.55% | |
| 64Neutral | $356.13B | 147.39 | 5.29% | 2.35% | 5.21% | -86.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 62.93 | 19.09 | 43.55% | |
| AMGN | Amgen Inc | 462.32 | 129.16 | 38.77% | |
| LLY | Eli Lilly And Company | 1431.67 | 388.38 | 37.23% | |
| MRK | Merck & Company | 144.46 | 52.12 | 56.45% | |
| NVS | Novartis AG | 160.20 | 35.33 | 28.30% | |
| ABBV | Abbvie | 294.55 | 68.41 | 30.25% |
Bristol-Myers Squibb Corporate Events
Bristol Myers Squibb Raises 2026 Outlook on Strong Q3
PositiveOn October 29, 2026, Bristol Myers Squibb reported third quarter 2026 results, with total revenues rising 7% year-on-year to $13.1 billion and U.S. sales up 9%, underpinned by a 12% increase to $7.7 billion in its Growth Portfolio. GAAP EPS came in a...
Bristol Myers Squibb Raises 2026 Revenue Outlook
PositiveOn July 30, 2026, Bristol Myers Squibb reported second-quarter 2026 results, highlighting a 6% year-on-year increase in total revenues to $13.0 billion and a 15% rise in Growth Portfolio sales to $7.6 billion, driven by Opdivo Qvantig, Reblozyl, Camz...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026
